Q3-osavuosiraportti
UUTTA
3 päivää sitten‧22 min
1,25 NOK/osake
Viimeisin osinko
5,81 %
Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
2 555
Myynti
Määrä
328
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 822 | - | - | ||
| 35 | - | - | ||
| 5 | - | - | ||
| 150 | - | - |
Ylin
21,8VWAP
Alin
21,4VaihtoMäärä
0,2 7 709
VWAP
Ylin
21,8Alin
21,4VaihtoMäärä
0,2 7 709
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 16.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 31.10. | |
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2024 Yhtiökokous | 22.5. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
26.10.·Analysis of Vistin Pharma ASA as a long-term investment Vistin Pharma ASA (OB: VISTN) is a Norwegian pharmaceutical company specializing in the production of metformin hydrochloride, an active pharmaceutical ingredient (API) and direct compressible (DC) product used primarily in the treatment of type 2 diabetes. The company produces approximately 10% of the world's demand for metformin HCl API, with a dedicated factory in Kragerø, Norway. The company has a strong focus on quality (cGMP compliance, FDA approved, nitrosamine-free production) and sustainability, including ISO 14001 certification and a recent long-term renewable energy agreement with Statkraft. 15 Capacity is expanding towards 7,000 tons per year, which positions the company well in a growing market driven by the increasing prevalence of diabetes globally (expected 850 million cases by 2050). 16 Financial performance and health Vistin Pharma shows solid financial performance with stable growth and high margins. For the first half of 2025 (H1), revenue increased by 11% to NOK 233 million, driven by 17% higher sales volume, while EBITDA rose by 27% to NOK 60.5 million (margin 26%). Operating profit (EBIT) was NOK 50.2 million, and net profit NOK 40.2 million, with EPS of NOK 0.91. 16 The balance sheet is strong with an equity ratio of 70% (NOK 294 million) and net debt of only NOK 40 million. Cash flow from operations was positive (NOK 11.8 million), although dividend payments (NOK 1.25 per share, totaling NOK 55 million) negatively impacted financing flow. 16 The share is currently trading around NOK 22 (as of October 2025), with a market capitalization of approximately NOK 980 million. 9 Key key figures include: • P/E ratio: 12.9x (low compared to the industry). • Gross margin: 66% (well above long-term target of 60%). • ROE: 24% (strong return on equity). • Dividend yield: 5.7% (payout ratio 73%). Historically, the stock has delivered good long-term returns: 68% in total over 3 years, but underperformed the market in the past year (-18% vs. Norwegian market +5%). 9 The stock is stable with low volatility (beta 0.64) and weekly movement of 2.8%. Growth prospects The metformin market is growing steadily, driven by rising diabetes rates. Global forecasts show a CAGR of 4–6% until 2030, with a market size of approx. USD 4 billion in 2022 to over USD 6 billion in 2030 for metformin overall, and the API segment from USD 350 million in 2025 to higher levels. 17 20 Vistin Pharma benefits from this through capacity expansion and strategic customer collaborations, with stable demand expected and no immediate impact from customs or supply chains. 16 The company’s European base provides a quality advantage over competitors in low-cost countries such as India (e.g. Aurobindo), and it faces limited competition in the premium API segment. 26 Analysts estimate a fair value of NOK 49, indicating a 55% undervaluation based on the current price. 9 Long-term potential is supported by a sustainability focus and operational efficiency, with plans for additional capex for growth. Risks Despite strengths such as high financial health (score 5/6) and historical performance (5/6), there are challenges: 9 • Low growth outlook: Analysts give a low score (0/6) on future growth, partly due to limited coverage (only 1 analyst). • Market dependence: As a pure API producer, the company is vulnerable to price fluctuations in generic pharmaceuticals and competition from Asia. • Regulatory and geopolitical risks: Changes in FDA regulations or trade barriers could affect exports (mainly globally). • Liquidity: Low trading volume and volatility in the small-cap market. Overall, the debt/equity ratio is low (14.5% debt/equity), and the company has a good buffer against downside. Conclusion Vistin Pharma appears to be an attractive long-term investment for investors seeking stable returns with dividends and undervaluation potential. The essential role in diabetes treatment, high margins and market growth outweigh the risks, especially with a 5.7% yield and a 55% discount to fair value. For the long-term horizon (5+ years), buying is recommended at prices below NOK 25, with a focus on the Q3 results on October 31 for confirmation. Always diversify, and consider your own risk tolerance – this is not investment advice. For more data, see the company's website or Oslo Børs.
16.10.·If this trend continues, it looks like Vistin will be by far my largest position going forward. What is it that people don't like about a stable business with increasing volume, prices and dividends?30.10.30.10.God timing når jeg holder på med å skalere ned forsvarsaksjene mine, fint å ha Vistin å putte penger i.
26.9.·As I understand it, Vistin Pharma will not be directly affected by the new Tariff. According to Reuters: «Trump announces 100% tariff on branded or patented pharmaceuticals». Metformin API is not considered a finished drug, patented drug or branded drug. It is a raw material (API). Therefore, Vistin Pharma’s products will not be subject to or directly affected by the new Tariff.- 24.9.·Should we expect dividends again at the end of the year? - maybe a stupid question?
24.9.·No, probably not. The way I see it, the dividend for 2023 was for some reason split into 2 portions, while the 2024 dividend was paid in one lump sum. So the next dividend will hopefully come with the Q4 2025 numbers.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
UUTTA
3 päivää sitten‧22 min
1,25 NOK/osake
Viimeisin osinko
5,81 %
Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 26.10.·Analysis of Vistin Pharma ASA as a long-term investment Vistin Pharma ASA (OB: VISTN) is a Norwegian pharmaceutical company specializing in the production of metformin hydrochloride, an active pharmaceutical ingredient (API) and direct compressible (DC) product used primarily in the treatment of type 2 diabetes. The company produces approximately 10% of the world's demand for metformin HCl API, with a dedicated factory in Kragerø, Norway. The company has a strong focus on quality (cGMP compliance, FDA approved, nitrosamine-free production) and sustainability, including ISO 14001 certification and a recent long-term renewable energy agreement with Statkraft. 15 Capacity is expanding towards 7,000 tons per year, which positions the company well in a growing market driven by the increasing prevalence of diabetes globally (expected 850 million cases by 2050). 16 Financial performance and health Vistin Pharma shows solid financial performance with stable growth and high margins. For the first half of 2025 (H1), revenue increased by 11% to NOK 233 million, driven by 17% higher sales volume, while EBITDA rose by 27% to NOK 60.5 million (margin 26%). Operating profit (EBIT) was NOK 50.2 million, and net profit NOK 40.2 million, with EPS of NOK 0.91. 16 The balance sheet is strong with an equity ratio of 70% (NOK 294 million) and net debt of only NOK 40 million. Cash flow from operations was positive (NOK 11.8 million), although dividend payments (NOK 1.25 per share, totaling NOK 55 million) negatively impacted financing flow. 16 The share is currently trading around NOK 22 (as of October 2025), with a market capitalization of approximately NOK 980 million. 9 Key key figures include: • P/E ratio: 12.9x (low compared to the industry). • Gross margin: 66% (well above long-term target of 60%). • ROE: 24% (strong return on equity). • Dividend yield: 5.7% (payout ratio 73%). Historically, the stock has delivered good long-term returns: 68% in total over 3 years, but underperformed the market in the past year (-18% vs. Norwegian market +5%). 9 The stock is stable with low volatility (beta 0.64) and weekly movement of 2.8%. Growth prospects The metformin market is growing steadily, driven by rising diabetes rates. Global forecasts show a CAGR of 4–6% until 2030, with a market size of approx. USD 4 billion in 2022 to over USD 6 billion in 2030 for metformin overall, and the API segment from USD 350 million in 2025 to higher levels. 17 20 Vistin Pharma benefits from this through capacity expansion and strategic customer collaborations, with stable demand expected and no immediate impact from customs or supply chains. 16 The company’s European base provides a quality advantage over competitors in low-cost countries such as India (e.g. Aurobindo), and it faces limited competition in the premium API segment. 26 Analysts estimate a fair value of NOK 49, indicating a 55% undervaluation based on the current price. 9 Long-term potential is supported by a sustainability focus and operational efficiency, with plans for additional capex for growth. Risks Despite strengths such as high financial health (score 5/6) and historical performance (5/6), there are challenges: 9 • Low growth outlook: Analysts give a low score (0/6) on future growth, partly due to limited coverage (only 1 analyst). • Market dependence: As a pure API producer, the company is vulnerable to price fluctuations in generic pharmaceuticals and competition from Asia. • Regulatory and geopolitical risks: Changes in FDA regulations or trade barriers could affect exports (mainly globally). • Liquidity: Low trading volume and volatility in the small-cap market. Overall, the debt/equity ratio is low (14.5% debt/equity), and the company has a good buffer against downside. Conclusion Vistin Pharma appears to be an attractive long-term investment for investors seeking stable returns with dividends and undervaluation potential. The essential role in diabetes treatment, high margins and market growth outweigh the risks, especially with a 5.7% yield and a 55% discount to fair value. For the long-term horizon (5+ years), buying is recommended at prices below NOK 25, with a focus on the Q3 results on October 31 for confirmation. Always diversify, and consider your own risk tolerance – this is not investment advice. For more data, see the company's website or Oslo Børs.
- 16.10.·If this trend continues, it looks like Vistin will be by far my largest position going forward. What is it that people don't like about a stable business with increasing volume, prices and dividends?30.10.30.10.God timing når jeg holder på med å skalere ned forsvarsaksjene mine, fint å ha Vistin å putte penger i.
- 26.9.·As I understand it, Vistin Pharma will not be directly affected by the new Tariff. According to Reuters: «Trump announces 100% tariff on branded or patented pharmaceuticals». Metformin API is not considered a finished drug, patented drug or branded drug. It is a raw material (API). Therefore, Vistin Pharma’s products will not be subject to or directly affected by the new Tariff.
- 24.9.·Should we expect dividends again at the end of the year? - maybe a stupid question?24.9.·No, probably not. The way I see it, the dividend for 2023 was for some reason split into 2 portions, while the 2024 dividend was paid in one lump sum. So the next dividend will hopefully come with the Q4 2025 numbers.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
2 555
Myynti
Määrä
328
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 822 | - | - | ||
| 35 | - | - | ||
| 5 | - | - | ||
| 150 | - | - |
Ylin
21,8VWAP
Alin
21,4VaihtoMäärä
0,2 7 709
VWAP
Ylin
21,8Alin
21,4VaihtoMäärä
0,2 7 709
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 16.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 31.10. | |
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2024 Yhtiökokous | 22.5. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
UUTTA
3 päivää sitten‧22 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 16.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 31.10. | |
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2024 Yhtiökokous | 22.5. | |
| 2025 Q1-osavuosiraportti | 25.4. | |
| 2024 Q4-osavuosiraportti | 13.2. |
Datan lähde: Millistream, Quartr
1,25 NOK/osake
Viimeisin osinko
5,81 %
Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 26.10.·Analysis of Vistin Pharma ASA as a long-term investment Vistin Pharma ASA (OB: VISTN) is a Norwegian pharmaceutical company specializing in the production of metformin hydrochloride, an active pharmaceutical ingredient (API) and direct compressible (DC) product used primarily in the treatment of type 2 diabetes. The company produces approximately 10% of the world's demand for metformin HCl API, with a dedicated factory in Kragerø, Norway. The company has a strong focus on quality (cGMP compliance, FDA approved, nitrosamine-free production) and sustainability, including ISO 14001 certification and a recent long-term renewable energy agreement with Statkraft. 15 Capacity is expanding towards 7,000 tons per year, which positions the company well in a growing market driven by the increasing prevalence of diabetes globally (expected 850 million cases by 2050). 16 Financial performance and health Vistin Pharma shows solid financial performance with stable growth and high margins. For the first half of 2025 (H1), revenue increased by 11% to NOK 233 million, driven by 17% higher sales volume, while EBITDA rose by 27% to NOK 60.5 million (margin 26%). Operating profit (EBIT) was NOK 50.2 million, and net profit NOK 40.2 million, with EPS of NOK 0.91. 16 The balance sheet is strong with an equity ratio of 70% (NOK 294 million) and net debt of only NOK 40 million. Cash flow from operations was positive (NOK 11.8 million), although dividend payments (NOK 1.25 per share, totaling NOK 55 million) negatively impacted financing flow. 16 The share is currently trading around NOK 22 (as of October 2025), with a market capitalization of approximately NOK 980 million. 9 Key key figures include: • P/E ratio: 12.9x (low compared to the industry). • Gross margin: 66% (well above long-term target of 60%). • ROE: 24% (strong return on equity). • Dividend yield: 5.7% (payout ratio 73%). Historically, the stock has delivered good long-term returns: 68% in total over 3 years, but underperformed the market in the past year (-18% vs. Norwegian market +5%). 9 The stock is stable with low volatility (beta 0.64) and weekly movement of 2.8%. Growth prospects The metformin market is growing steadily, driven by rising diabetes rates. Global forecasts show a CAGR of 4–6% until 2030, with a market size of approx. USD 4 billion in 2022 to over USD 6 billion in 2030 for metformin overall, and the API segment from USD 350 million in 2025 to higher levels. 17 20 Vistin Pharma benefits from this through capacity expansion and strategic customer collaborations, with stable demand expected and no immediate impact from customs or supply chains. 16 The company’s European base provides a quality advantage over competitors in low-cost countries such as India (e.g. Aurobindo), and it faces limited competition in the premium API segment. 26 Analysts estimate a fair value of NOK 49, indicating a 55% undervaluation based on the current price. 9 Long-term potential is supported by a sustainability focus and operational efficiency, with plans for additional capex for growth. Risks Despite strengths such as high financial health (score 5/6) and historical performance (5/6), there are challenges: 9 • Low growth outlook: Analysts give a low score (0/6) on future growth, partly due to limited coverage (only 1 analyst). • Market dependence: As a pure API producer, the company is vulnerable to price fluctuations in generic pharmaceuticals and competition from Asia. • Regulatory and geopolitical risks: Changes in FDA regulations or trade barriers could affect exports (mainly globally). • Liquidity: Low trading volume and volatility in the small-cap market. Overall, the debt/equity ratio is low (14.5% debt/equity), and the company has a good buffer against downside. Conclusion Vistin Pharma appears to be an attractive long-term investment for investors seeking stable returns with dividends and undervaluation potential. The essential role in diabetes treatment, high margins and market growth outweigh the risks, especially with a 5.7% yield and a 55% discount to fair value. For the long-term horizon (5+ years), buying is recommended at prices below NOK 25, with a focus on the Q3 results on October 31 for confirmation. Always diversify, and consider your own risk tolerance – this is not investment advice. For more data, see the company's website or Oslo Børs.
- 16.10.·If this trend continues, it looks like Vistin will be by far my largest position going forward. What is it that people don't like about a stable business with increasing volume, prices and dividends?30.10.30.10.God timing når jeg holder på med å skalere ned forsvarsaksjene mine, fint å ha Vistin å putte penger i.
- 26.9.·As I understand it, Vistin Pharma will not be directly affected by the new Tariff. According to Reuters: «Trump announces 100% tariff on branded or patented pharmaceuticals». Metformin API is not considered a finished drug, patented drug or branded drug. It is a raw material (API). Therefore, Vistin Pharma’s products will not be subject to or directly affected by the new Tariff.
- 24.9.·Should we expect dividends again at the end of the year? - maybe a stupid question?24.9.·No, probably not. The way I see it, the dividend for 2023 was for some reason split into 2 portions, while the 2024 dividend was paid in one lump sum. So the next dividend will hopefully come with the Q4 2025 numbers.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
2 555
Myynti
Määrä
328
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | - | - | ||
| 822 | - | - | ||
| 35 | - | - | ||
| 5 | - | - | ||
| 150 | - | - |
Ylin
21,8VWAP
Alin
21,4VaihtoMäärä
0,2 7 709
VWAP
Ylin
21,8Alin
21,4VaihtoMäärä
0,2 7 709
Välittäjätilasto
Dataa ei löytynyt